| 戎佩佩.信迪利单抗治疗胸腺瘤引发免疫性心肌炎 1例[J].安徽医药,2021,25(6):1239-1241. |
| 信迪利单抗治疗胸腺瘤引发免疫性心肌炎 1例 |
| A case analysis of immune checkpoint inhibitor myocarditis induced by Sindilimab in treating thymoma |
| |
| DOI：10.3969/j.issn.1009-6469.2021.06.044 |
| 中文关键词: 胸腺瘤 心肌炎 信迪利单抗 程序性死亡受体 1(PD-1) 免疫检查点抑制剂 病例分析 |
| 英文关键词: Thymoma Myocarditis Sintilimab Programmed death 1 (PD-1) Immune checkpoint inhibitor Case analysis |
| 基金项目: |
|
| 摘要点击次数: 1961 |
| 全文下载次数: 382 |
| 中文摘要: |
| 目的探讨信迪利单抗用于胸腺瘤致免疫性心肌炎的发生机制和药学监护方法。方法报道 2019年 9月 20日武汉大学人民医院 1例信迪利单抗用于胸腺瘤致免疫性心肌炎的病例，并进行相关文献分析。结果病人使用信迪利单抗两周后出现喘气、心慌，心脏生化及心电图存在异常，诊断为免疫性心肌炎，行激素冲击等治疗后恢复正常［肌酸激酶同工酶( CKMB) 3.69 μg/L，肌红蛋白( MYO)46.24 μg/L，超敏肌钙蛋白( ultra-TnI)0.030 μg/L，N端脑钠肽前体( NT-proBNP)59.00 ng/L］。结论免疫性心肌炎为罕见而严重的不良反应，本研究报道了国内首例信迪利单抗引起的免疫性心肌炎，临床药师应予以关注。 |
| 英文摘要: |
| Objective To explore the mechanism and pharmaceutical care of Sindilimab-induced myocarditis.Methods A case of immune checkpoint inhibitor myocarditis induced by Sindilimab, who was treated at Renmin Hospital of Wuhan University on September 20, 2019, was reported and the literature was reviewed.Results Two weeks after treatment with Sindilimab, the patient developeddyspnea, palpitation, abnormal cardiac biochemistry and ECG, then was diagnosed as immune checkpoint inhibitor-related myocarditis.After steroid pulse therapy and support treatment, the patient′s condition clinically improved (CKMB 3.69 μg/L, MYO 46.24 μg/L, ul‐tra-TnI 0.030 μg/L, NT-proBNP 59.00 ng/L).Conclusion Immune checkpoint inhibitor myocarditis is a rare but serious adverse reaction. This study reported the first case of immune checkpoint inhibitor myocarditis caused by Sindilimab in China, and clinical pharmacists should pay attention to it. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
